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Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplanta-
tion. We conducted a randomized, controlled trial to test the efficacy and safety of pre-
transplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-a2b/RBV) for
prevention of post-transplant HCV recurrence. Enrollees had HCVand were listed for liver
transplantation, with either potential living donors or Model for End-Stage Liver Disease
upgrade for hepatocellular carcinoma. Patients with HCV genotypes (G) 1/4/6 (n 5 44/2/
1) were randomized 2:1 to treatment (n 5 31) or untreated control (n 5 16); HCV G2/3
(n532) were assigned to treatment. Overall, 59 were treated and 20 were not. Peg-IFN-
a2b, starting at 0.75 lg/kg/week, and RBV, starting at 600 mg/day, were escalated as toler-
ated. Patients assigned to treatment versus control had similar baseline characteristics.
Combined virologic response (CVR) included pretransplant sustained virologic response
and post-transplant virologic response (pTVR), defined as undetectable HCV RNA 12
weeks after end of treatment or transplant, respectively. In intent-to-treat analyses, 12
(19%) assigned to treatment and 1 (6%) assigned to control achieved CVR (P 5 0.29);
per-protocol values were 13 (22%) and 0 (0%) (P 5 0.03). Among treated G1/4/6
patients, 23 of 30 received transplant, of whom 22% had pTVR; among treated G2/3
patients 21 of 29 received transplant, of whom 29% had pTVR. pTVR was 0%, 18%, and
50% in patients treated for <8, 8-16, and >16 weeks, respectively (P 5 0.01). Serious
adverse events (SAEs) occurred with similar frequency in treated versus untreated patients
(68% versus 55%; P5 0.30), but the number of SAEs per patient was higher in the treated
group (2.7 versus 1.3; P 5 0.003). Conclusion: Pretransplant treatment with Peg-IFN-a2b/
RBV prevents post-transplant recurrence of HCV in selected patients. Efficacy is higher
with >16 weeks of treatment, but treatment is associated with increased risk of potentially
serious complications. (HEPATOLOGY 2013;57:1752-1762)
*This is publication 18 of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Transplantation Cohort Study; AE, adverse event; ANC, absolute neutrophil count; b-DNA, branched-
chain DNA; CHC, chronic hepatitis C; CI, confidence interval; Cr, creatinine; CTP, Child-Turcotte-Pugh (class or score); CVR, combined virologic response;
DDLT, deceased donor liver transplantation; DSMB, data and safety monitoring board; EPA, erythropoietin analog; GCRC, General Clinical Research Centers;
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transplantation; MELD, Model for End-Stage Liver Disease; Peg-IFN-a2b, pegylated IFN alpha-2b; PCR, polymerase chain reaction; PLT, platelet; PP, per
protocol; pTVR, post-transplant virologic response; RBV, ribavirin; RCT, randomized, controlled trial; RNA, ribonucleic acid; SAE, serious adverse event; SC,
subcutaneously; SD, standard deviation; SVR 12, pretransplant sustained virologic response; SVR, sustained virologic response; TMA, transcription-mediated
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ecurrence of hepatitis C virus (HCV) infection
is inevitable in viremic patients undergoing
liver transplantation (LT).1,2 Aggressive recur-
rence of hepatitis C is associated with rapid progres-
sion to cirrhosis, graft failure, and death or need for
LT.3-5 Prevention of allograft reinfection by pretrans-
plant antiviral therapy is one strategy for improving
graft and patient outcomes in recipients transplanted
for chronic hepatitis C (CHC).
Virologic response to pegylated interferon (Peg-IFN)
and ribavirin (RBV) is reduced in cirrhosis. In the
registration trials for Peg-IFN/RBV, the rates of sus-
tained virologic response (SVR) were 5%-15% lower
in patients with advanced fibrosis or cirrhosis.6-8 Like-
lihood of SVR further diminishes with increasing se-
verity of liver disease as the result of poor tolerability,
dose reductions, discontinuation of therapy, and
intrinsically compromised response to Peg-IFN/RBV.9-
11 SVR was only demonstrated in 13% of patients
with HCV genotype 1 and decompensated liver dis-
ease, two thirds of whom were treatment naı¨ve.12
Despite the reduced rates of SVR among patients
with advanced liver disease, on-treatment clearance of
HCV ribonucleic acid (RNA) from blood can be
achieved in 30%-40% of patients with HCV genotype
1 and 70%-90% of patients with HCV genotypes 2 or
3. In the setting of LT, rendering blood free of HCV
RNA before transplantation could potentially limit the
risk for recurrent HCV after LT. Five published reports
have suggested that suppression of HCV RNA in
patients with advanced disease is achievable, and that
20%-30% of treated patients may remain free of HCV
infection after transplantation.12-16 None of these
reports was a randomized trial, limiting conclusions
regarding efficacy and, more important, safety.
Herein, we report the efficacy and safety of Peg-
IFN/RBV to prevent the recurrence of HCV in a
cohort of patients from the Adult-to-Adult Living Do-
nor Liver Transplantation Cohort Study (A2ALL).
Patients and Methods
Study Patients. Patients were enrolled from Octo-
ber 2005 to January 2009 and were followed through
December 2009. Two groups of adult patients with
chronic HCV infection listed for LT were included:
those who had a potential living donor and those with
hepatocellular carcinoma (HCC) eligible for Model for
End-Stage Liver Disease (MELD) waiting list upgrade.
These two patient groups were considered the best
candidates for pretransplant HCV treatment because
they typically had less-severe liver decompensation and
therefore would be predicted to better tolerate therapy.
Another feature of these two groups is a relatively
short, predictable duration of time on the waiting list
that allowed for timing of treatment. Key inclusion
criteria were stable clinical status, HCV RNA positive,
MELD 20, and anticipated time to transplantation
of at least 12 weeks. The protocol allowed an investi-
gator to petition for enrollment of a patient with a
MELD score from 21 to 25. A clinical oversight com-
mittee (G.E., A.L., and N.T.) was created to review
the clinical information and determine eligibility for
enrollment. Only 1 case (MELD 22) was approved
and enrolled under this provision.
The main exclusion criteria were history of null
response to a previous course of full doses of Peg-IFN and
RBV for at least 12 weeks, symptomatic cardiovascular or
psychiatric disease or serious systemic illness, active
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substance abuse within the previous 6 months, severe cyto-
penias not responsive to either erythropoietin analog
(EPA) or granulocyte colony-stimulating factor (G-CSF),
and unstable clinical courses related to ongoing gastroin-
testinal bleeding, refractory encephalopathy, or HCC
beyond Milan criteria. Exclusionary laboratory criteria
were creatinine (Cr) 2.2 mg/dL, hemoglobin (Hb) <10
g/dL, absolute neutrophil count (ANC) <750/uL, and
platelets (PLT) <35,000/uL before initiation of therapy.
EPA and G-CSF were allowed before enrollment to
achieve these laboratory entry criteria.
The protocol was approved by the institutional
review boards at the participating institutions, and all
subjects provided written informed consent.
Study Design. Eligible patients were enrolled at
seven clinical centers; patients infected with genotypes
1/4/6 were randomized 2:1 to treatment or observation
using a web-based interface stratified by clinical center,
whereas those with HCV genotypes 2/3 were assigned to
treatment. The different approach by genotype reflected a
known lower virologic response to Peg-IFN/RBV for ge-
notypes 1/4/6 than for genotypes 2/3 as well as the need
to include untreated controls to assess treatment risk. The
targeted duration of therapy (12 weeks) was anticipated
to be necessary to achieve virologic response. The risk of
deferring transplantation was also considered. The intent
was to treat patients up to the time of transplantation or
for a maximum of 48 weeks. Treatment assignments were
not blinded at any stage.
Treatment, using a low accelerating dose regimen
(LADR), was initiated with Peg-IFN-a-2b (0.75 lg/
kg/week) and RBV (600 mg/day). Dose escalations
were performed at weeks 1 (Peg-IFN 1.5 lg/kg/week
and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3
(RBV 1.2 g/day for patients who weighed more than
75 kg) based upon patient tolerance and weekly blood
counts. Dose escalation of Peg-IFN required ANC
>750/lL and PLT >35,000/lL; dose escalation of
RBV required Hb >10g/dL. Once a patient reached
the target RBV dose of 1-1.2 g/day (approximately
10.6-13.2 mg/kg/day), no further increases in RBV
dose were made. Subsequent doses of Peg-IFN and
RBV were adjusted based upon adverse events (AEs),
patient tolerability, and blood counts. If the highest tol-
erated dose of Peg-IFN was <0.5 ug/kg, Peg-IFN was
permanently discontinued. EPA (PROCRIT 10,000-
40,000 U weekly subcutaneously; SC) and G-CSF
(NEUPOGEN 150-300 lg SC up to three times/week)
were allowed before and during antiviral treatment if
Hb <12.5 mg/dL or ANC <1,000/uL, respectively.
Per protocol, antibiotic prophylaxis was required for
patients randomized to treatment who had a history of
spontaneous bacterial peritonitis or low protein ascites.
After several serious infections, the protocol was
amended to administer prophylactic antibiotics to all
patients with current or past history of ascites.
Patients were observed every 2 weeks until week 12,
then monthly until transplantation or completion of
48 weeks of treatment. Complete blood counts, inter-
national normalized ratio (INR) of prothrombin time,
and chemistry profile were measured at each visit and
more often when clinically indicated. For those com-
pleting 48 weeks of treatment or undergoing trans-
plantation, follow-up was every 12 weeks for 24 weeks
post-treatment or 48 weeks post-transplantation.
Efficacy Assessments. The primary endpoint was
post-transplant virologic response (pTVR), defined as
undetectable HCV RNA at week 12 after LT. Pretrans-
plant SVR (SVR12) was defined as undetectable HCV
RNA at week 12 after end of treatment. Combined viro-
logic response (CVR) comprised both SVR12 and pTVR.
Patient management required that HCV RNA was
quantified locally. Assays differed by clinical center;
some assayed HCV RNA by polymerase chain reaction
(PCR) assays with limit of detection (LOD) of 50 IU/
mL, whereas others used branched-chain DNA (b-DNA)
assays with LOD of 615 IU/mL. Serum samples were
also stored for subsequent HCV RNA measurement by a
central laboratory. The latter samples were first analyzed
by b-DNA assay, and all samples with undetectable
results (<615 IU/mL) were then retested by transcrip-
tion-mediated amplification (TMA) with LOD of 5 IU/
mL. For data analysis, HCV RNA central laboratory
results were supplemented with local results when sam-
ples were missing or insufficient for central testing.
Safety Assessments. Safety measures included physi-
cal examination, AE assessment, and laboratory moni-
toring. Cytopenias with Hb <8 g/dL, ANC <500/uL,
or PLT <20,000/uL required treatment interruption or
discontinuation. Serious adverse events (SAEs) included
standard World Health Organization criteria and spe-
cific events related to cirrhosis or LT. SAEs were eval-
uated for relationship to antiviral treatment by the site
principal investigators. Deaths were reviewed by an
oversight committee (G.E., A.L., and N.T.) and the
data and safety monitoring board (DSMB) for A2ALL
to evaluate relationship, if any, to antiviral treatment.
The DSMB reviewed safety data quarterly and met
twice per year to review study progress.
Statistical Analyses. Efficacy was tested first using
intent-to-treat (ITT) analyses and subsequently using
per protocol (PP) analyses; safety analyses were con-
ducted using PP analyses. Descriptive statistics were
reported as mean and standard deviation (SD) or
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percentages, as appropriate. Treatment balance over
clinical and laboratory characteristics was tested by
Student’s t test for continuous variables and chi-square
test for categorical variables. Variables predictive of
pTVR were tested by logistic regression; covariates
tested included baseline HCV RNA, HCV genotype,
graft type, treatment duration, use of growth factors
during treatment, and achievement of 80% target dose of
Peg-IFN and RBV. Proportions of SAEs in treated and
untreated patients were compared using two-sided Fish-
er’s exact tests; SAE rates were compared using Poisson
regression. The time to first HCV RNA negativity was
estimated by Kaplan Meier method, with censoring at
death, but not at transplant. The distributions of HCV
RNA by treatment week were estimated using the reverse
Kaplan Meier method to account for data below LOD.17
Sample size was calculated for patients with geno-
types 1, 4, 5, or 6 assuming a 2:1 randomization (a ¼
0.05) and two-sided testing to detect a difference in
pTVR of 30% in treated versus 1% in control patients
with 89% power (n ¼ 84 transplanted patients). This
enrollment target was not achieved (n ¼ 47 with ge-
notypes 1/4/6 enrolled, 35 transplanted), and recruit-
ment was terminated to allow complete follow-up of en-
rolled patients before the end of funding. This analysis
combines genotypes 2/3 with genotypes 1/4/6. Although
an interim analysis was planned after half of the expected
genotype 1/4/5/6 patients were transplanted (n ¼ 40),
this analysis was not carried out because of low enroll-
ment. Statistical analyses were performed using SAS 9.2
software (SAS Institute Inc., Cary, NC), with tests per-
formed at a significance level of 0.05.
Results
A total of 145 patients with chronic HCV, includ-
ing 92 with HCC, were potentially eligible for this
study. Eighty-seven (60% of all eligible HCV cases),
including 49 with HCC (53% of the HCC cases), were
enrolled; 8 were screen failures and 79 were assigned to
treatment groups (Fig. 1). Reasons for failure to enroll
the remaining 58 patients were intolerance to previous
interferon (IFN), unwillingness to take IFN-based treat-
ment, null response to previous therapy, ‘‘too sick,’’ con-
traindications to IFN or RBV, or inability to comply
with visit schedule or study protocol.
Patients with HCV genotypes 1/4/6 (n ¼ 44/2/1)
were randomized 2:1 to treatment (n ¼ 31) or
untreated control (n ¼ 16). HCV genotypes 2/3 (n ¼
32) were all assigned to treatment. Overall, 59 were
treated with Peg-IFN/RBV and 20 were not treated.
Of the 47 patients with HCV genotype 1/4/6, 2
patients assigned to treatment were never treated and
1 patient assigned to control was treated. Three of the
thirty-two patients with HCV genotype 2/3 did not
receive treatment. Reasons for lack of treatment in the
5 patients assigned to treatment were early transplant,
consent withdrawal, death, worsening renal function,
and unknown. One control patient requested and
received treatment off-protocol.
Baseline Characteristics. Demographic, clinical,
and laboratory characteristics of the patients are shown
in Table 1. The assigned treatment and control groups
were well matched with respect to age, gender, ethnic-
ity, race, weight, blood counts, baseline HCV RNA
levels, and laboratory assessment of liver and renal
function. In addition, mean (6 SD) MELD score
(12.0 6 3.3 versus 12.0 6 3.8), and Child-Turcotte-
Pugh (CTP) mean (6 SD) score (7.0 6 1.5 versus
6.3 6 1.4) were similar. The treatment group had
fewer patients with MELD upgrade for HCC (54%
versus 94%; P ¼ 0.003). Sixty-two percent of treated
patients and 56% of controls were IFN experienced.
The duration of previous therapy and the type of viro-
logic response to previous therapy (i.e., relapse, partial
response, and null response) was not determined.
Virologic Response During Treatment with
LADR. Cumulative distributions of HCV RNA results
at baseline and during LADR treatment are given in
Supporting Fig. 1 for HCV genotypes 1/4/6 (Support-
ing Fig. 1A) and HCV genotypes 2/3 (Supporting Fig.
1B). Patients with HCV genotypes 2/3 had more
rapid, greater suppression of HCV RNA during
LADR treatment.
Fig. 1. Enrollment flow chart by HCV genotype, showing both ITT
and treatment PP groups. All 32 patients infected with HCV genotypes 2
or 3 were assigned to treatment, but only 29 initiated treatment and 3
never received Peg-IFN or RBV. Forty-seven patients were infected with
HCV genotypes 1, 4, or 6, of whom 31 were assigned to treatment and
16 were assigned to untreated control. Two of the patients assigned to
treatment never received Peg-IFN or RBV, and 1 control was treated. The
8 screen failures are not reflected in this diagram.
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Figure 2 shows time to first negative HCV RNA
level during LADR treatment for patients achieving
CVR. The probability of undetectable HCV RNA at
week 16 was similar between patients with HCV geno-
types 1/4/6 versus HCV genotypes 2/3 (log-rank test:
P ¼ 0.89). Among patients who had CVR, all
achieved undetectable HCV RNA by week 16.
CVR. For ITT analysis, 12 (19%) of the 63 treat-
ment-group patients and 1 (6%) of the 16 control-
group patients achieved CVR (P ¼ 0.29) (Table 2).
CVRs included 2 SVRs and 11 pTVRs. The single
control CVR was the patient who requested and
received treatment, achieved SVR, and did not
undergo LT, despite being randomized to no treat-
ment. For the PP analysis, 13 (22%) of the 59 treated
(95% confidence interval [CI]: 0.12, 0.35) and none
of the untreated group achieved CVR (P ¼ 0.03).
A higher proportion of patients with CVR had a
>2-log10 IU/mL decrease in HCV RNA by treatment
week 4 (89% versus 68%) or week 8 (100% versus
70%) and undetectable HCV RNA by week 12
(100% versus 32%), compared to patients not achiev-
ing CVR (Supporting Table 1).
LT. Fifty-seven patients, 44 treated and 13 controls,
underwent LT: 16 living donor liver transplantations
(LDLTs) and 41 deceased donor liver transplantations
(DDLTs). Because of our selection criteria, more
patients who underwent DDLT had HCC upgrade
(90% versus 6%; P < 0.0001). As a result, the DDLT
group had lower laboratory MELD and CTP scores.
Otherwise, the LDLT and DDLT groups had similar
demographics, HCV genotype distribution, and mean
baseline HCV RNA. Among those treated and trans-
planted, the proportions with pTVR were not signifi-
cantly different: 5 of 16 (31%) pTVR in LDLT versus
6 of 28 (21%) in DDLT (P ¼ 0.49).
Twenty-two patients were not transplanted and 7 of
these had died, 1 each from liver failure, renal failure,
multiorgan system failure, cardiac arrest, status epilepti-
cus, sepsis, and unknown. Of the 15 who were alive at
the end of follow-up, 2 had achieved SVR and were clin-
ically stable, 8 were still listed and awaiting transplanta-
tion, 3 were delisted for progression of HCC, and 2
were delisted for severe deterioration in liver disease and
clinical status.
Virologic Responses in Transplanted Patients. None
of the 13 controls, but 26 of 44 (59%) treated
patients, achieved undetectable HCV RNA by the
time of transplantation (P < 0.0001). Of the 44
Table 1. Baseline Characteristics of Patients by Assigned
Treatment Group
Treatment (n ¼ 63) Control (n ¼ 16)
Characteristics Mean (SD) or N (%) Mean (SD) or N (%) P Value
Age, years 56 (7.0) 56 (5.4) 0.71
Gender (%)
Male 46 (73) 13 (81) 0.75
Ethnicity (%)
Hispanic 15 (24) 2 (12) 0.50
Race (%)
White 53 (84) 11 (69)
African American 3 (5) 2 (12) 0.28
Other 7 (11) 3 (19)
Weight (kg) 84 (15.3) 88 (13.5) 0.31
BMI (kg/m2) 28 (4.4) 29 (4.9) 0.45
HCV characteristics
Genotype (%)
1 30 (47) 14 (88)
2 16 (24) 0 (0)* <0.001
3 16 (25) 0 (0)*
4 or 6 1 (4) 2 (12)
Viral load (log10 IU/mL) 5.7 (1.0) 5.7 (0.6) 0.99
HCC upgrade (%) 34 (54) 15 (94) 0.003
Laboratory tests
Hemoglobin (g/dL) 13.1 (1.7) 13.5 (1.3) 0.40
WBC (103/mm3) 4.7 (1.7) 4.2 (1.1) 0.35
ANC (/mm3) 794 (1,402) 531 (962) 0.48
PLT (103/mm3) 92 (53) 93 (42) 0.98
Albumin (g/dL) 3.2 (0.6) 3.3 (0.6) 0.83
AST (IU/L) 111 (69) 101 (45) 0.59
ALT (IU/L) 84 (59) 79 (40) 0.74
Total bilirubin (mg/dL) 2.1 (1.4) 2.2 (1.6) 0.73
Creatinine (mg/dL) 0.9 (0.3) 0.9 (0.2) 0.81
INR 1.3 (0.2) 1.3 (0.2) 1.00
MELD 12.0 (3.3) 12.0 (3.8) 0.96
CTP Score 7.0 (1.5) 6.3 (1.4) 0.11
Previous IFN treatment (%) 39 (62) 9 (56) 0.68
Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; ANC,
absolute neutrophil count; PLT, platelet; MELD, Model for End-stage Liver Dis-
ease; CTP, Child-Turcotte-Pugh (class or score); IFN, interferon; BMI, body mass
index; WBC, white blood cell count; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase; INR, international normalized ratio.
*By study design, all HCV genotype 2/3 patients were assigned to treatment.
Fig. 2. Cumulative probability distribution, among treated patients,
of time from study enrollment to first HCV RNA negativity for patients
who achieved either SVR12 or pTVR, estimated by Kaplan-Meier.
Dashed line shows the distribution for patients with HCV genotypes 1/
4/6, and solid line for HCV genotypes 2/3.
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treated patients, 52% with HCV genotypes 1/4/6 and
67% with genotypes 2/3 had undetectable HCV RNA
at transplantation (Fig. 3).
The proportion with pTVR was comparable in ITT
and PP analyses (Table 2). Eleven of the twenty-six
(42%) treated patients who had undetectable HCV
RNA at transplantation achieved pTVR, 13 (50%)
relapsed, and 2 (8%) died before week 12 post-trans-
plant. None of the controls achieved pTVR (P ¼ 0.03).
pTVR did not differ between patients with HCV geno-
types 1/4/6 (5 of 23; 22%) versus patients with HCV
genotypes 2/3 (6 of 21; 29%) (P ¼ 0.60) (Fig. 3). All
11 patients with pTVR were retested at post-transplant
week 24 and all remained HCV RNA undetectable.
The LOD of the test used to detect HCV RNA at
transplant made a substantial difference in predicting
pTVR. For the 26 patients with HCV RNA undetect-
able at transplant, 8 were tested using assays with
LOD of 5 IU/mL, compared to 18 tested using assays
with LOD >5 IU/mL, and the pTVR was 75% and
28%, respectively, in these groups (P ¼ 0.038).
Predictors of pTVR. Likelihood of pTVR increased
with the duration of treatment. In patients who
received <8, 8-16, and >16 weeks of treatment,
pTVR was 0%, 18%, and 50%, respectively (P ¼
0.01) (Fig. 4). In univariate PP analyses, duration of
pretransplant RBV (categorized; P ¼ 0.01) and Peg-
IFN (categorized; P ¼ 0.05) were the only factors sig-
nificantly associated with pTVR (Table 3). Although
other factors were not significant, patients experiencing
pTVR were more likely to be infected with HCV ge-
notypes 2/3, had lower baseline HCV RNA, used
growth factors during treatment, and achieved target
doses of Peg-IFN and RBV.
Table 2. Proportions and 95% CIs by Genotype of CVR* and pTVR
Genotype Analysis
CVR Among
All Patients
pTVR Among
Transplanted Patients
pTVR Among Transplanted Patients
HCV RNA Negative at Transplant
1/4/6 ITT 6/31 ¼ 0.19 (0.07-0.37) 5/24 ¼ 0.21 (0.07-0.42) 5/12 ¼ 0.42 (0.15-0.72)
PP 7/30 ¼ 0.23 (0.09-0.42) 5/23 ¼ 0.22 (0.07-0.44) 5/12 ¼ 0.42 (0.15-0.72)
2/3 ITT 6/32 ¼ 0.19 (0.07-0.36) 6/22 ¼ 0.27 (0.11-0.50) 6/14 ¼ 0.43 (0.18-0.71)
PP 6/29 ¼ 0.21 (0.08-0.40) 6/21 ¼ 0.29 (0.11-0.52) 6/14 ¼ 0.43 (0.18-0.71)
All ITT 12/63 ¼ 0.19 (0.10-0.31) 11/46 ¼ 0.24 (0.13-0.39) 11/26 ¼ 0.42 (0.23-0.63)
PP 13/59 ¼ 0.22 (0.12-0.35) 11/44 ¼ 0.25 (0.13-0.40) 11/26 ¼ 0.42 (0.23-0.63)
*Includes patients who achieved SVR (SVR12 and not transplanted) or pTVR.
Abbreviations: CVR, combined virologic response; SVR12, pretransplant sustained virologic response; pTVR, post transplant virologic response; ITT, intent to treat;
PP, per protocol.
Fig. 3. Percent of treated patients with undetectable HCV RNA at
transplant and at week 12 post-LT by genotype. Overall, 59% of 44
treated patients were HCV RNA negative at time of transplant and 25%
achieved pTVR (RNA negative at post-transplant week 12). Fifty-two per-
cent of 23 genotype (G) 1/4/6 and 67% of 21 G 2/3 were RNA negative
at transplant (P ¼ 0.33); and 22% of G 1/4/6 and 29% of G 2/3
achieved pTVR (P ¼ 0.60). PP analyses; whiskers are61 standard error.
Fig. 4. Percent of treated patients with undetectable HCV RNA at
transplant and at week 12 post-LT (pTVR) by treatment duration. Viro-
logic response to pretransplant therapy was linked to treatment dura-
tion. Only 25% of the patients treated for less than 8 weeks had
undetectable HCV RNA at transplant, and none achieved pTVR. In con-
trast, 64% of patients treated for more than 16 weeks had undetect-
able HCV RNA at transplant, and 50% achieved pTVR. PP analyses;
whiskers are 61 standard error.
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SAEs and Death. SAEs before and up to 1 year af-
ter LT are listed in Table 4. There was no significant
difference in the proportion of treated patients and
controls that experienced SAEs (68% versus 55%; P ¼
0.30), but the number of SAEs per patient was greater
in treated patients (2.7 versus 1.3; P ¼ 0.003). There
was no association between MELD score and either
the total number of SAEs or SAEs resulting from
infection (data not shown).
Before LT, a greater proportion of treated patients had
SAEs (46% versus 20%; P ¼ 0.04). SAEs of cytopenia
(19% versus 0%; P ¼ 0.06) and infection (12% versus
0%; P ¼ 0.18) were only observed in treated patients.
Liver-related SAEs occurred with similar frequency
(treated versus control, 14% versus 15%; P¼ 1.0).
Infection was more common in treated patients. As
mentioned above, 7 of 59 treated patients (12%) and
0 of 20 controls (0%) experienced an SAE of infection.
Nineteen of fifty-nine treated patients (20%) and 2 of
20 controls (10%) experienced an AE of infection.
Rates of infection in treated patients may have been
reduced by antibiotic prophylaxis. SAEs of infection
occurred in 10% (5 of 48) of patients receiving pro-
phylaxis, compared to 18% (2 of 11) not receiving
prophylaxis. AEs of infection occurred in 29% (14 of
48) of patients receiving prophylaxis, compared to
45% (5 of 11) not receiving prophylaxis.
SAEs also tended to be more common in treated
patients early after transplantation. Within the first 30
days, a greater proportion of treated patients had
SAEs, compared to controls (32% versus 15%; P ¼
0.31), and infection was only observed in treated
patients (9% versus 0%; P ¼ 0.56).
Between 30 days and 1 year post-transplantation,
we found that a similar proportion of treated patients
and controls had experienced an SAE (55% versus
46%; P ¼ 0.59), but treated patients had more SAEs
per patient (2.1 versus 1.2; P ¼ 0.06). Rejection
within the first year occurred in 1 treated patient and
in none of the control patients (2% versus 0%; P ¼
1.0).
Despite the greater risk for SAEs, pretransplant
treatment was not associated with increased risk of
death: 9 (15%) treated patients and 2 (10%) controls
died (log-rank test: P ¼ 0.81). Five of the treated
patients and 2 of the untreated patients died pre-LT.
Overall, mortality rates were 7.0% (4 of 57) in trans-
plant recipients, compared to 31.8% (7 of 22) in those
without a transplant.
Dose and Duration of Peg-IFN and RBV. Patients
achieving pTVR had higher exposure to both Peg-IFN
and RBV. Cumulative doses per kilogram of body
weight, duration of treatment, and percentages of
patients achieving 80% of target doses for both Peg-
IFN and RBV trended higher in the patients achieving
pTVR (Supporting Table 2).
Growth Factors. Forty-four of the fifty-nine treated
patients (75%) received growth factors (9 received G-
CSF alone, 14 received EPA alone, and 21 received
both G-CSF and EPA). Ten of the eleven patients
Table 3. Predictors of pTVR Among Those Transplanted Who Were Assigned to Treatment (ITT, n 5 46)
or Who Received Treatment (PP, n 5 44)
ITT analysis PP Analysis
Variables OR 95% CI P Value OR 95% CI P Value
Baseline HCV RNA log10 IU/mL 0.54 0.26-1.12 0.10 0.53 0.26-1.10 0.09
Baseline HCV RNA >5.5 versus 5.5 log10 IU/mL 0.34 0.08-1.38 0.13 0.29 0.07-1.19 0.09
HCV genotype: 1/4/6 versus 2/3 0.70 0.18-2.74 0.61 0.69 0.18-2.73 0.60
LDLT versus DDLT 1.81 0.46-7.26 0.40 1.67 0.42-6.69 0.47
Duration of pre–liver transplant treatment
Peg-IFN
Number of weeks (continuous) 1.09 0.99-1.19 0.09 1.08 0.98-1.19 0.14
Categorized
>16 1 1
8-16 0.36 0.08-1.64 0.03 0.36 0.08-1.64 0.05
<8 0.11 0.01-1.11 0.13 0.01-1.35
RBV
Number of weeks (continuous) 1.09 0.99-1.20 0.07 1.09 0.97-1.20 0.10
Categorized
>16 1 1
8-16 0.24 0.06-1.08 0.004 0.24 0.06-1.08 0.01
<8 0.05 0.002-1.12 0.06 0.002-1.45
Use of growth factors during treatment 4.58 0.52-40.38 0.17 3.75 0.42-33.61 0.24
Ability to achieve 80% of target dose of both Peg-IFN and RBV 3.38 0.63-17.96 0.15 2.93 0.54-15.75 0.21
Abbreviation: OR, odds ratio; pTVR, post transplant virologic response; ITT, intent to treat; PP, per protocol; HCV, hepatitis C virus; LDLT, living donor liver trans-
plantation; DDLT, deceased donor liver transplantation; IFN, interferon; RBV, ribavirin.
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achieving pTVR (91%), compared to 24 of 33
patients without pTVR (73%) (P ¼ 0.41), used
growth factors during the course of pretransplant ther-
apy (Supporting Table 2).
Discussion
LADR-A2ALL is the first randomized, controlled
trial (RCT) of pretransplant treatment of CHC using
Peg-IFN plus RBV to prevent recurrent HCV infec-
tion after transplantation. LADR-A2ALL sought to
determine the efficacy of pretransplant treatment to
prevent recurrent HCV and included an untreated
control group to define the safety of Peg-IFN and
RBV when used in this setting. Pretransplant treat-
ment achieved post-transplant clearance of HCV
pTVR in 25%. However, treatment was associated
with an increased frequency of SAEs, including
infection.
In LADR-A2ALL, 59% of patients were HCV
RNA negative at the time of transplant. This rate of
on-treatment viral clearance was higher than noted in
previous reports using comparable doses of IFN, or
Peg-IFN, with RBV. In the reports by Everson et al.,12
Forns et al.,14 and Carrion et al.,16 32%, 35%, and
35% of patients were HCV RNA negative at the time
of transplantation—approximately half the virologic
response achieved in LADR-A2ALL. One contributing
factor to the higher on-treatment virologic response
may have been the relatively higher proportion of
Table 4. SAEs in Untreated and Treated Patients Pre-LT, in the First 30 Days Post-LT, and 30 Days to 1 Year Post-LT
Treated Untreated P Value
Overall
Number of patients with SAEs % 40/59 (68) 11/20 (55) 0.300
Total number of events 109 14
Number of SAEs/patient among those with SAEs 2.7 1.3 0.003
Number of deaths* % 9/59 (15) 2/20 (10) 0.810†
Pre-LT
Number of patients with SAEs % 27/59 (46) 4/20 (20) 0.040
Total number of SAEs 42 5
Number of events/patient among those with SAEs 1.6 1.3 0.520
Cytopenia All % 11 (19) 0 (0) 0.060
Neutropenia 6 0
Thrombocytopenia 5 0
Infection All % 7 (12) 0 (0) 0.180
SBP 3 0
Other 4 0
Liver related All % 8 (14) 3 (15) 1.000
Liver failure 6 3
Other 2 0
Other % 11 (19) 1 (5) 0.280
Post-LT, first 30 days
Number of patients with SAEs % 14/44 (32) 2/13 (15) 0.310
Total number of SAEs 17 2
Number of events/patient among those with SAEs 1.2 1.0 0.460
Cytopenia % 0 0 1.000
Infection % 4 (9) 0 0.560
Liver related % 3 (7) 1 (8) 1.000
Rejection % 1 (2) 0 1.000
Surgical complication % 2 (5) 0 1.000
Other % 7 (16) 1 (8) 0.670
Post-LT, 30 days to 1 year
Number of patients with SAEs % 24/44 (55) 6/13 (46) 0.590
Total number of SAEs 50 7
Number of events/patient among those with SAEs 2.1 1.2 0.060
Cytopenia % 0 2 (15) 0.050
Infection % 9 (20) 3 (23) 1.000
Liver related % 2 (5) 0 1.000
Rejection % 0 0 1.000
Surgical complication % 8 (18) 0 0.180
Other % 13 (30) 2 (15) 0.480
Abbreviation: SBP, spontaneous bacterial peritonitis; SAE, serious adverse events; LT, liver transplantation.
*Causes of death in these 11 patients were cardiac arrest (n ¼ 2), sepsis (n ¼ 2), heart failure (n ¼ 2), liver failure (n ¼ 1), renal failure (n ¼ 1), cerebral
edema (n ¼ 1), and unknown (n ¼ 2).
†Based on log-rank test.
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patients infected with HCV genotypes 2/3. The per-
centage of patients infected with HCV genotypes 2 or
3 in other studies ranged from 17% to 33%.13-16,18 In
LADR-A2ALL, 53% of treated patients were infected
with HCV genotype 2 or 3. Another factor may have
been the exclusion from the study of patients with pre-
vious null response to Peg-IFN and RBV.
The higher on-treatment virologic response in
LADR-A2ALL could also have been the result of the
use of a variety of HCV RNA assays, with LODs as
high as 615 IU/mL. A significant proportion of
patients with undetectable HCV RNA by these insen-
sitive assays were likely still viremic. This conclusion is
supported by our TMA results, where pTVR was
achieved in 75% of patients with undetectable HCV
RNA by TMA, compared to only 28% of patients
with undetectable HCV RNA, by the less-sensitive
assays. This experience indicates that future treatment
trials must use centralized sensitive assays to accurately
define viral kinetics and virologic responses.
The percentage pTVR achieved in LADR-A2ALL
(25%) was similar to pTVR percentages achieved in
the reports by Everson et al. (26%), Forns et al.
(23%), and Carrion et al. (23%). The relapse rate in
LADR-A2ALL of 50% was higher than that observed
by Everson et al. (20%), Forns et al. (33%), and Car-
rion et al. (33%).12,14,16 The higher rate of relapse in
LADR-A2ALL was likely related, at least in part, to
the high proportion of patients who received a short
duration of treatment. In our univariate analyses, the
only factor predictive of pTVR was longer duration of
pretransplant treatment. Shorter duration of treatment
was associated with higher likelihood of relapse—
100% of patients receiving less than 8 weeks of treat-
ment relapsed.
Maintaining adequate doses and blood levels of
RBV may be particularly important when using lower
doses or dose reductions in Peg-IFN.18 In LADR-
A2ALL, patients experiencing pTVR were more likely
to have achieved 80% of their targeted dose of RBV
(91% versus 70%) and to have remained on RBV lon-
ger (17.3 versus 12.9 weeks). Patients achieving pTVR
were more likely to have used EPA, a factor that could
have allowed greater exposure to RBV and improved
the likelihood of clearing HCV.19
Factors predicting virologic response in patients
with advanced stages of CHC have been noted in
other studies. Everson et al. found three factors predic-
tive of SVR in 124 patients with advanced hepatitis C:
infection with HCV genotype 2 or 3 (compared to ge-
notypes 1/4/6), CTP class A cirrhosis (compared to
CTP classes B and C), and dose and duration of IFN
(or Peg-IFN) and RBV treatment.12 Similar observa-
tions were made by Forns et al., Carrion et al., and
Thomas et al.14-16 Carrion et al. also demonstrated
that ‘‘early’’ virologic response (>2 log10 IU/mL
decrease by week 4) during treatment predicted likeli-
hood for pTVR.16 In LADR-A2ALL, pTVR was only
possible in the patients who were HCV RNA negative
by week 12. The findings of Carrion et al. and
LADR-A2ALL suggest that treatment could be discon-
tinued in patients who either fail to achieve a 2-log10
drop in HCV RNA by week 8 when using standard
doses of Peg-IFN/RBV or who remain HCV RNA
positive at week 12 when treated with LADR.
Pretransplant treatment with Peg-IFN plus RBV is
only applicable to a select group of patients. We en-
rolled two types of patients into our study—potential
recipients of LDLT who had an identifiable donor
undergoing evaluation and potential recipients of
DDLT who met criteria for MELD upgrade for HCC.
These patients generally have less-severe liver disease,
compared to patients awaiting DDLT for complica-
tions of liver failure, and are therefore able to better
tolerate the AEs associated with Peg-IFN/RBV. Addi-
tionally, in these two patient groups, the interval
between initiation of Peg-IFN/RBV treatment and
transplantation is somewhat predictable. In the case of
LDLT, the date of transplantation can be scheduled. In
the case of DDLT for HCC after MELD upgrade,
transplantation would typically occur within 6 months
after the MELD upgrade. In some centers in the
United States, LT may be performed at relatively low
MELD scores, and the time interval between listing
and transplantation can be estimated. Patients with
HCV awaiting DDLT in these low-MELD centers
might also be candidates for pretransplant treatment.
However, practical logistical issues, such as underlying
HCC and need for urgent transplantation or availabil-
ity of donor liver, compromise the ability to extend
treatment duration.
In LADR-A2ALL, treated patients experienced more
SAEs and infection. In the case-control study of Car-
rion et al.,16 treated patients had a significantly
increased risk for bacterial infection (P < 0.001). The
increased risk of infection indicates that prophylactic
antibiotics during antiviral therapy may be warranted.
Experience in both LADR-A2ALL and Barcelona sug-
gested that antibiotic prophylaxis may have lowered
the risk for bacterial infection during Peg-IFN/RBV
treatment.
Nine treated patients (15%) and 2 control patients
(10%) died. In the absence of a control group, the
mortality rate in treated patients might be viewed as
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excessive and related to antiviral therapy. However, the
similar mortality rate of controls suggests that our
observed mortality rate might represent the underlying
risk of mortality in these patients on the waiting list
before and after hepatic transplantation. Support for
this interpretation is provided by the case-control
study of Carrion et al.16 Mortality rates were nearly
identical to rates we reported in LADR-A2ALL—8
deaths in 51 treated patients (16%) versus 7 deaths in
51 case controls (14%).
Limitations of the study included failure to reach
enrollment target, inability to complete planned
minimum duration of treatment of 12 weeks for many
subjects, partly resulting from the timing of DDLT
availability, incomplete HCV RNA follow-up, incon-
sistency of LODs of HCV RNA assays, and noncom-
pliance with assigned treatment in a few patients. Gen-
eralizability of results is primarily for the U.S.
Caucasian population. Strengths of the study include
randomization among HCV genotypes 1/4/6, allowing
comparison of AEs between treated patients and
controls.
In summary, we conducted an RCT of Peg-IFN and
RBV in 79 patients with advanced hepatitis C who were
candidates for LT. Pretransplant treatment prevented
post-transplant recurrence of HCV infection in 25% of
transplanted cases—22% in HCV genotypes 1/4/6 and
29% in HCV genotypes 2/3. The strongest predictor of
virologic response was duration of treatment. Despite
these potentially significant therapeutic benefits, Peg-
IFN and RBV were poorly tolerated in these ‘‘difficult-
to-treat’’ and ‘‘difficult-to-cure’’ patients. SAEs, some
potentially life threatening, occurred during the course
of treatment. Future treatments incorporating direct-act-
ing antivirals that accelerate and enhance virologic
response should improve rates of pTVR, but will require
strategies to limit toxicity.
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